Skip to main content
Top
Published in: Current Hypertension Reports 3/2017

01-03-2017 | Hot Topic

Method of Blood Pressure Measurement, Interpretation of SPRINT, and the Atlantic Divide

Author: John M. Flack

Published in: Current Hypertension Reports | Issue 3/2017

Login to get access

Excerpt

Use of unattended automated office blood pressure (BP) measurement (AOBPM) in the SPRINT trial has been the focus of much discussion with divergence of opinion regarding its impact on the interpretation of the SPRINT trial results [1]. The rationale for words of caution, provided by most recently by colleagues from across the Atlantic at the 2016 European Society of Cardiology meeting in Rome, (http://​cardiobrief.​org/​2016/​09/​06/​sprint-more-controversy-and-confusion-about-landmark-trial/​) when extrapolating the SPRINT trial results to clinical practice settings, centers on the lower BP obtained with unattended AOBPM than with routine single office BP measurements. In fact, unattended AOBPM measurements are ∼14/7 mmHg lower than routine office BP measurements. On the surface, this seems like a legitimate concern—or is it? …
Literature
1.
go back to reference SPRINT Research Group, Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16. doi:10.1056/NEJMoa1511939.CrossRef SPRINT Research Group, Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16. doi:10.​1056/​NEJMoa1511939.CrossRef
2.
go back to reference Flack JM, Nolasco C, Levy P. The case for low blood pressure targets. Am J Hypertens. 2017;30:3–7.CrossRefPubMed Flack JM, Nolasco C, Levy P. The case for low blood pressure targets. Am J Hypertens. 2017;30:3–7.CrossRefPubMed
4.
go back to reference Liu K, Colangelo LA, Daviglus ML, Goff DC, Pletcher M, Schreiner PJ, et al. Can antihypertensive treatment restore the risk of cardiovascular disease to ideal levels?: the Coronary Artery Risk Development in Young Adults (CARDIA) study and the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Heart Assoc. 2015;4(9):e002275. doi:10.1161/JAHA.115.002275.CrossRefPubMedPubMedCentral Liu K, Colangelo LA, Daviglus ML, Goff DC, Pletcher M, Schreiner PJ, et al. Can antihypertensive treatment restore the risk of cardiovascular disease to ideal levels?: the Coronary Artery Risk Development in Young Adults (CARDIA) study and the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Heart Assoc. 2015;4(9):e002275. doi:10.​1161/​JAHA.​115.​002275.CrossRefPubMedPubMedCentral
Metadata
Title
Method of Blood Pressure Measurement, Interpretation of SPRINT, and the Atlantic Divide
Author
John M. Flack
Publication date
01-03-2017
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 3/2017
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-017-0719-0

Other articles of this Issue 3/2017

Current Hypertension Reports 3/2017 Go to the issue

Novel Treatments for Hypertension (T Unger, Section Editor)

A Review of the Genetics of Hypertension with a Focus on Gene-Environment Interactions

Hypertension and Metabolic Syndrome (J Sperati, Section Editor)

Selenium, Vanadium, and Chromium as Micronutrients to Improve Metabolic Syndrome

Hypertension and Metabolic Syndrome (J Sperati, Section Editor)

Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol

Preeclampsia (VD Garovic, Section Editor)

Pre-eclampsia: the Potential of GSNO Reductase Inhibitors

Secondary Hypertension: Nervous System Mechanisms (M Wyss, Section Editor)

Defining the Relationship Between Hypertension, Cognitive Decline, and Dementia: a Review

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.